Ryan Polselli, as a part of running his company MammoLink®, is in the process of partnering with several cancer awareness and research organizations that support those suffering from cancer, people who have overcome a diagnosis, and ensuring that everyone gets screened before cancer takes over their lives. In addition to advocating for better cancer screening technology and techniques, Dr. Polselli has forged partnerships with the American Cancer Society, Susan G. Omen, and battered women’s shelters in his community to make sure everyone gets the testing and care they deserve.
Ryan Polselli has a wealth of experience ensuring that patients get the best cancer screening services possible. Early detection is the key to most treatment plans, and getting quality, complete, accurate information the first time is crucial to helping patients get the treatment they need to fight their cancer diagnosis. Dr. Polselli works hard because he has seen too many patients fall through the cracks in their cancer screenings, leading to unnecessary extreme treatments and unfortunate events that needn’t have happened.
Ryan Polselli is a diagnostic radiologist working as the head of Breast Imaging at Global Imaging Specialists, which specializes in diagnostic and scanning services for all patients. Early detection in cancer cases means more saved lives and better treatment all around. So Dr. Polselli, after working in his field of medicine for a few years, decided to create his own breast imaging services. He founded MammoLink®, a company dedicated to redefining the traditional relationship between patients and doctors, which Dr. Polselli has seen fail to deliver results in too many cases to let go any longer.
MammoLink® has made it easier for family medicine physicians and OB-GYNs to treat breast health problems before they become life-threatening. Physicians need the best information to make the best decisions. MammoLink® makes that information easier to access and utilize.
Ryan Polselli hopes his membership in the healthcare community and his ongoing work can improve the medical experience for cancer patients long into the future
Ryan Polselli, the founder of the revolutionary breast cancer screening company MammoLink®, was born in Dunedin, Florida and raised primarily in Clearwater, Florida. He went to a Christian school and spent a great deal of time in the water or at the beach from a young age. Dr. Polselli learned how to swim before he could walk and soon spent much of his free time fishing, waterskiing, and scuba diving. In sixth grade, he received a culture-shock when he moved to Alaska, where he lived with his family in Wasilla and Eagle River.
Dr. Ryan Polselli is a successful Breast Imaging Radiologist who interprets over 20,000 2D and 3D mammograms per year. In his roles as lead interpreting Breast Imaging Radiologist for four outpatient imaging centers.
Leading authorities in the world of the science and technology of breast imaging were mentors for Dr. Ryan Polselli. Original members of the first BIRADS (Breast Imaging-Reporting and Data System) committee and experts who created the FDA standards for mammography reporting, as well as members of the American College of Radiology appropriateness advisory committees and distinguished faculty members were all part of the superior preparation of Dr. Polselli.
Ryan Polselli started his medical career in Diagnostic Radiology, which he was recognized for in his early years as a doctor. In 2012, he became the Director of Breast Imaging at Memorial Health University Medical Center in Savannah, Georgia. Dr. Polselli developed and implemented interventional MRI services and protocols, including the groundbreaking MRI-Guided breast biopsies. His methodology and expertise helped raise the detection rate of breast cancer in patients screened at Memorial Health.
Ryan Polselli is now a Breast Imaging and General Radiologist for Global Imaging Specialists and the founder and CEO of MammoLink, a company that provides state-of-the-art, fully customizable mammogram technology to healthcare providers throughout the United States. Treating breast cancer often comes down to how early the disease is detected. With regular screening, women lower their risk of dying from the disease significantly. Dr. Polselli saw a need for better detection technology in this area, so he applied his expertise and experience to help.
Ryan Polselli has devoted his time in the healthcare field to helping women detect breast cancer as early as possible.
Also Read - https://ryanpolselli.wordpress.com/2017/11/24/ryan-polselli-supporting-breast-cancer-awareness/
INNOVATIVE APPROACH TO FEASIBLY INTEGRATE HIGH RISK BREAST CANCER SCREENING INTO A PRIVATE RADIOLOGY PRACTICE BY RYAN POLSELLI
Click to set custom HTML
There are many considerations that go into a surgical plan. I cannot list them all and I do not pretend to know all of them. A breast surgeon is better equipped to answer this question for you. He or she should know the details of this answer and what would be best under any given circumstances. I defer to their expertise. I cannot understate this.
However, this is my understanding of general treatment guidelines for stage 0 breast cancer which is also known as DCIS, or in other words, cancer that is still contained within the ducts of the breast.
First, I have to make some assumptions here because the information was not provided in your question, but let's assume that you or someone you know was recently diagnosed with DCIS from a core needle biopsy.
This most commonly, but not always, occurs in the setting of stereotactic guided core needle biopsy of suspicious calcifications in the breast seen on a mammogram. Less commonly (about 10 percent of the time) DCIS can actually present as a mass and is then sometimes diagnosed with an ultrasound guided core biopsy.
In any event, as long as a lumpectomy is going to be performed (the most common surgical procedure for DCIS discovered on needle biopsy), sentinel lymph node biopsy can be skipped if it is not very “likely” that there is any invasive cancer that was missed on the original biopsy. This is fairly subjective and may take into account local and regional differences as well as surgeon and patient considerations and preferences.
Up to approximately 10 percent of the time (depends on the research that you read) what was believed to be DCIS from a needle biopsy actually ends up showing that there was an invasive cancer when lumpectomy is performed. In this case the traditional guidelines still recommend sentinel node biopsy. In this cases, many of these patients would then need a second biopsy.
In order to avoid this, if there is a larger area of suspicious calcification than what was biopsied originally biopsied, then a sentinel biopsy may be wise to perform at the time of initial surgery. On the other end of the spectrum, if a large core needle was used for the original biopsy and the entire area of suspicion was removed, it's not likely that the DCIS will be upstaged to invasive breast cancer at the time of surgery and sentinel mode biopsy may not be necessary.
Obviously there are many many more considerations that come into play so the final recommendations from surgeons may still differ from what I have described. Additionally, a lot of newer research is being published that challenges the status quo about stage 0 breast cancer and which may come into play when designing a treatment plan. Finally, guidelines are constantly being refined so there is always a certain lag time as general practice patterns catch up and this also can contribute to different recommendations.
As stated earlier in this answer for you, I strongly recommend that you visit with your surgeon and or oncologist to discuss the treatment plan that is best for you. I hope this helps.
Ryan Polselli, MD, Diplomate of the American Board of Radiology, Fellowship Trained Breast Imaging Radiologist
The above information is intended as general information and is not intended to be medical advice.
For more information about topics related to breast cancer screening and diagnosis, visit Dr. Ryan Polselli's blog, Mammography Matters. You can also obtain more information at his facebook page, Dr. Ryan Polselli. Please visit and like!
In short it depends. I will speak generically about this.
Different tumors, infections, cancers, organs, and types of needle biopsy techniques have different risks of needle track seeding. Any needle biopsy should take these risks into account and only be performed when the patient gives consent and the benefits of the biopsy outweigh the risks (which include needle track seeding). In this setting, as long as the technique is performed properly, even if seeding were to occur, it would not be considered by most in the profession of medicine to be a medical error. In some cases seeding is irrelevant.
However, failure of any of the above could potentially imply a medical error. For example, failure to consent a patient is considered an error. So is performing a biopsy when the risk outweighs the benefit (this can be subjective) or if the technique is performed improperly and causes potentially harmful seeding.
Two points of caution about this topic because we are not talking specifics. One, I don't want anyone to assume biopsy track seeding has occurred just because there is disease progression. It is common for us as humans to assign blame and or assign a cause and effect relationships where it doesn't exist.
Two, there are many situations where needle track seeding never occurs and should not weigh into the consideration about whether or not to have a biopsy. For example, core needle biopsies of breast cancers do not result in seeding and concept of seeding in this case is irrelevant and should never deter anyone from having a breast biopsy. There are many other examples.
Ryan Polselli, M.D., Diplomate of the American Board of Radiology, Fellowship Trained Breast Imaging Radiologist